Wainwright ConferenceGlad they gave a week's notice. I *may* be able to shuffle my schedule to listen in live. The Kellum effect is making a difference already. ; ) Spectral Medical to Participate at the Upcoming H.C. Wainwright Global Life Sciences Conference MAR 2, 2021 TORONTO, CANADA March 2, 2021 Spectral Medical Inc. (Spectral or the Company) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (Dialco), today announced that Spectrals executive management team, including Dr. Paul Walker, President and CEO, Chris Seto, COO & CFO, and Dr. John Kellum, CMO, will be participating at the H.C. Wainwright Global Life Sciences Conference which will be held virtually on March 9-10, 2021. A link to the presentation will be available under Events, Webcasts and Presentations in the investors section of Spectrals website at 7:00 a.m. ET, Tuesday, March 9, 2021 for a limited time. About Spectral Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, T Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Companys Endotoxin Activity Assay (EAA), the only FDA cleared diagnostic for the risk of developing sepsis. PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 200,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year. Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new proprietary platform, SAMI, targeting the renal replacement therapy (RRT) market. Dialco is also seeking regulatory approval for in-home use of DIMI which is based on the same RRT platform, but will be intended for home hemodialysis use. DIMI recently received its FDA 510k clearance for use in hospital and clinical settings. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com.